Abbott Launches Humira For Crohn's Disease treatment

Abbott has introcued the HUMIRA as a new treatment for severe Crohn's disease that is actively affecting the patients.

It has been informed that Adalimumab has become the very first fully-human tumour necrosis factor antagonist (anti-TNF) that is receiving a

licence for the treatment of Crohn's disease. Adalimumab is a completely human monoclonal antibody that performs its activity by blocking the current activity of TNF.

Adalimumab has become the second anti-TNF licenced for Crohn's disease, but apart from this, it has become the first to offer patients the

convenience of self-injection at home, which is a highly advanced step in the direction of Crohn's disease treatment.